Market Cap 2.57B
Revenue (ttm) 0.00
Net Income (ttm) -234.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,099,200
Avg Vol 469,752
Day's Range N/A - N/A
Shares Out 76.54M
Stochastic %K 1%
Beta 1.26
Analysts Strong Sell
Price Target $57.28

Latest News on XENE

Xenon to Present at Stifel 2025 Virtual CNS Forum

Mar 12, 2025, 4:01 PM EDT - 21 days ago

Xenon to Present at Stifel 2025 Virtual CNS Forum


Xenon Outlines Key Corporate Milestone Opportunities for 2025

Jan 13, 2025, 8:30 AM EST - 2 months ago

Xenon Outlines Key Corporate Milestone Opportunities for 2025


Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

Nov 25, 2024, 8:30 AM EST - 4 months ago

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024


Xenon to Present at Upcoming Investor Conferences

Nov 13, 2024, 4:01 PM EST - 5 months ago

Xenon to Present at Upcoming Investor Conferences


Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:49 PM EST - 5 months ago

Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript


Xenon Reports Q3 2024 Financial Results and Business Update

Nov 12, 2024, 4:01 PM EST - 5 months ago

Xenon Reports Q3 2024 Financial Results and Business Update


Xenon to Report Q3 2024 Financial Results on November 12, 2024

Nov 5, 2024, 4:01 PM EST - 5 months ago

Xenon to Report Q3 2024 Financial Results on November 12, 2024


Xenon Reports Q2 2024 Financial Results and Business Update

Aug 8, 2024, 4:01 PM EDT - 8 months ago

Xenon Reports Q2 2024 Financial Results and Business Update


Xenon to Report Q2 2024 Financial Results on August 8, 2024

Aug 1, 2024, 4:01 PM EDT - 8 months ago

Xenon to Report Q2 2024 Financial Results on August 8, 2024


Xenon Pharmaceuticals Announces Proposed Public Offering

Nov 29, 2023, 4:03 PM EST - 1 year ago

Xenon Pharmaceuticals Announces Proposed Public Offering


Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip

Nov 26, 2023, 4:55 AM EST - 1 year ago

Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip